Literature DB >> 30329009

When is Alzheimer's not dementia-Cochrane commentary on The National Institute on Ageing and Alzheimer's Association Research Framework for Alzheimer's Disease.

Jenny McCleery1, Leon Flicker1,2, Edo Richard1,3, Terence J Quinn1,4.   

Abstract

Early 2018 saw the release of new diagnostic guidance on Alzheimer's disease from the National Institute on Ageing and the Alzheimer's Association (NIA-AA). This proposed research framework represents a fundamental change in how we think about Alzheimer's disease, moving from diagnosis based on clinical features to diagnosis based solely on biomarkers. These recommendations are contentious and have important implications for patients, clinicians, policy makers and the pharmaceutical industry. In this commentary, we offer a summary of the NIA-AA research framework. We then focus on five key areas: divorcing neuropathology from the clinical syndrome; the emphasis placed on one dementia subtype; validity of available biomarkers; the changing meaning of the term 'Alzheimer's disease'; and the potential for a research framework to influence clinical practice.
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; Cochrane; biomarkers; dementia; evidence-based medicine; older people; research

Mesh:

Substances:

Year:  2019        PMID: 30329009     DOI: 10.1093/ageing/afy167

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  4 in total

1.  Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study.

Authors:  Aku Kaipainen; Olli Jääskeläinen; Yawu Liu; Fanni Haapalinna; Niko Nykänen; Ritva Vanninen; Anne M Koivisto; Valtteri Julkunen; Anne M Remes; Sanna-Kaisa Herukka
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  A typology of clinical conditions.

Authors:  Steven Tresker
Journal:  Stud Hist Philos Biol Biomed Sci       Date:  2020-05-22

Review 3.  The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

Authors:  Martí Colom-Cadena; Tara Spires-Jones; Henrik Zetterberg; Kaj Blennow; Anthony Caggiano; Steven T DeKosky; Howard Fillit; John E Harrison; Lon S Schneider; Phillip Scheltens; Willem de Haan; Michael Grundman; Christopher H van Dyck; Nicholas J Izzo; Susan M Catalano
Journal:  Alzheimers Res Ther       Date:  2020-03-02       Impact factor: 6.982

4.  An analytic framework for conceptualisations of disease: nine structuring questions and how some conceptualisations of Alzheimer's disease can lead to 'diseasisation'.

Authors:  Kristin Zeiler
Journal:  Med Health Care Philos       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.